The company plans to invest in its IndianapolisDiagnostics Site, the project will continue until2030 Year. It hopes to make the plant (asRoche Diagnostics North American headquarters) becomes the manufacturer of itsCGM The Main Center of the System.

Roche stated that its Indianapolis site hosts key operations, including U.S. R&D, laboratories, manufacturing, and distribution.IT And administrative functions. It currently produces approximately52 100 million recordsAccu-Chek Diabetes Test Strips.

The company expects the expansion will create hundreds of high-skilled manufacturing jobs and thousands of construction jobs.It can also improveUnited StatesIncrease production capacity and reduce reliance on imports. This not only strengthens local manufacturing but also potentially addresses the tariff issues implemented by the Trump administration.

President and CEO of Roche Diagnostics North AmericaBrad Moore Say："The challenge of diabetes is universal, with millions of Americans living under the constant vigilance and countless daily decisions that this disease demands. By expanding our manufacturing capacity in Indianapolis, we ensure that people with diabetes in the U.S. and around the world can reliably access innovative monitoring solutions."。”

Roche ofCGM Technology pipeline includesAccu-Chek SmartGuide System. The company in2024Annual Advanced Technologies and Treatments for Diabetes (ATTD) conference, it was the first time to launch itsAccu-Chek SmartGuide. It was2024 Year7 Month obtainedCGM TheCE Logo. Currently, the latest generation system has not yet been approved.FDA Approved.

Accu-Chek SmartGuide Has14 Daily wear time, one-step construction process, and waterproof performance. The system also utilizes predictiveAI Provide glucose prediction, showing estimated development across different time frames. According toCGM Data, the application of this system will display the possible blood glucose levels within the next two hours.CGM Sensor every5 Minutes send the real-time measured blood glucose values to the application.

Then, the predictive application uses these values and other available information to detect patterns and predict future blood glucose levels. IntegratedAI Contributes to the next30 Indicates hypoglycemia risk within minutes. It also helps predict hypoglycemic levels and estimate the risk of nocturnal hypoglycemia.

RocheCGM The clinical evaluation yielded an average absolute relative difference (MARD) (MeasureCGM The indicator of accuracy) is9.2%。Roche The report states,99.8% The measured glucose value is located in the Parkes Error GridA Area andB Area.CGM The predictive capability also exceeds performance requirements such as accuracy, sensitivity, specificity, and detected events.